Archives

Immunomodulatory signal presentation via synthetic hydrogel material promotes generation of T regulatory cells (green) in the local graft microenvironment (CD3+ T cells in red, and nuclei staining in blue) after implantation into a clinically relevant transplant model for the treatment of type 1 diabetes. (Credit: Georgia Tech)
UofL-born technology for treating Type 1 diabetes has commercial partner
LOUISVILLE, Ky. — A University of Louisville-born therapy that helps people with Type 1 diabetes stay off immunosuppressants by re-educating the body’s immune system...
UofL Trager Institute
UofL Trager Institute works to reduce social isolation for older adults through technology innovation Initiatives to benefit older adults during pandemic to be discussed in weekly information session Aug. 4
LOUISVILLE, Ky. – Amid efforts to stem the spread of the COVID-19 pandemic, social isolation and loneliness have emerged as a significant public health...
Allen Morris, executive director of the UofL Commercialization EPI-Center
UofL, partners will help commercialize Kentucky university-born technologies New effort, backed by $1.15 million from the Commonwealth, will encourage growth of innovative companies in Kentucky
LOUISVILLE, Ky. — The University of Louisville and partners will lead an effort to bring technologies born at Kentucky universities to market, thanks to...
Phase II results of Co-Immunity Project show higher-than-expected rates of exposure to novel coronavirus in Jefferson County Study finds 4-6 times higher rates of exposure to the virus than previously detected
LOUISVILLE, Ky. – Results from the second phase of the University of Louisville’s groundbreaking project to track COVID-19 in Jefferson County show that 4...
Geoffrey Clark, Ph.D.
UofL technology that may inhibit pathway for cancer gets commercial partner Researchers say the technology could solve “one of the holy grails” of cancer treatment
LOUISVILLE, Ky. — A University of Louisville-born invention that may help treat cancer now has a commercial partner. Qualigen Therapeutics Inc., a California biotechnology company...
A clinical trial for Aviptadil (RLF-100) is underway at UofL for severe COVID-19 patients. Image courtesy NeuroRx.
UofL conducting clinical trial on drug for severe COVID-19 respiratory effects
LOUISVILLE, Ky. — The University of Louisville is conducting a clinical trial on a new treatment for critically ill COVID-19 patients meant to lessen...
Jason Saleem, Ph.D., and doctoral student Jacob Read
UofL researchers testing virtual COVID-19 care tool for veterans Automated text messaging service aims to reassure patients and reduce stress on VA facilities
Members of the Media: Video of the researchers is available for download here. LOUISVILLE, Ky. – Researchers at the University of Louisville are working...
Brad Rodu, D.D.S.
NEWS TIP: UofL harm reduction expert says FDA approval of tobacco system as useful for smoking cessation is “good news for Americans”
LOUISVILLE, Ky. – On July 7, the US Food and Drug Administration approved Philip Morris International’s IQOS heat-not-burn tobacco product system status as a...
Students in the UofL Equine Industry Program.
UofL Equine Industry Program and KEEP launch second round of COVID-19 Kentucky Equine Business Impact Survey
The University of Louisville Equine Industry Program and the Kentucky Equine Education Project (KEEP) have released the second round of their COVID-19 Kentucky Equine...
UofL chemistry graduate student Jacob Strain conducts a catalysis experiment at the Conn Center. UofL photo by Tom Fougerousse.
UofL researchers developing method to convert carbon dioxide to usable products Project to develop CO2 catalysts receives funding from National Science Foundation
LOUISVILLE, Ky. – Scientists at the University of Louisville received new support for developing a method to sustainably sequester and convert carbon dioxide to...